

Istituto Nazionale Tumori

[View the current Istituto Nazionale Tumori Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/5894-Istituto+Nazionale+Tumori.html)

(<http://www.bioportfolio.com/biocorporate/5894-Istituto+Nazionale+Tumori.html>)

Contact Details:

Via G. Venezian 1

Milan

Milano

I-20133

Italy

Tel: 39 02 2390641

Fax: 39 02 2390764

Email:

Recent Publications by Istituto Nazionale Tumori:



- [Extremity Soft Tissue Sarcoma in a Series of Patients Treated at a Single Institution: The Local Control Directly Impacts Survival.](#)
*PURPOSE:: To improve understanding of what is adequate in local treatment...*5th February, 2010
From the Departments of *Surgery, daggerBiostatistics, double- Ann Surg. 2010 Feb 2. ([DOI Direct Link](#))
- [Simultaneous confidence intervals to compare gene expression profiles using ABC transporter TaqMan microfluidic cards.](#)
*The rapid evolution of techniques for measuring gene expression makes...*4th February, 2010
Medical Statistics and Biometry Unit, Department of Experimental Oncology- Oncol Rep. 2010 Mar;23(3):853-60.
- [\[Thinking about the power of modern medicine.\]](#)
*The rapid evolution of techniques for measuring gene expression makes...*4th February, 2010
Istituto Nazionale Tumori, Milano.- Epidemiol Prev. 2009 Jul-Oct;33(4-5):135-8.
- [Comparison of the Prognostic Value of Assessing Tumor Diameter Versus Tumor Volume at Diagnosis or in Response to Initial Chemotherapy in Rhabdomyosarcoma.](#)
*PURPOSE: In this study on a series of 205 patients with rhabdomyosarcoma,...*4th February, 2010
Pediatric Oncology Unit, Division of Medical Statistics and Biometry, and- J Clin Oncol. 2010 Feb 1. ([DOI Direct Link](#))
- [Beyond genome-wide association studies: genetic heterogeneity and individual predisposition to cancer.](#)
*Genome-wide association studies (GWAS) using population-based designs have...*29th January, 2010

Department of Predictive and for Prevention Medicine, Fondazione IRCCS,- Trends Genet. 2010 Jan 25. ([DOI Direct Link](#))

- [MicroRNAs and future therapeutic applications in cancer.](#)
*Every cellular process is likely to be regulated by microRNAs (miRNAs),...*27th January, 2010
Molecular Biology Unit, Department of Experimental Oncology, Fondazione- J BUON. 2009 Sep;14 Suppl 1:S17-22.
- [Tumor response to sunitinib malate observed in clear-cell sarcoma.](#)
*Every cellular process is likely to be regulated by microRNAs (miRNAs),...*23rd January, 2010
Adult Sarcoma Medical Oncology Unit, Department of Cancer Medicine,- Ann Oncol. 2010 Jan 21. ([DOI Direct Link](#))
- [Human CD34+ cells engineered to express membrane-bound tumor necrosis factor-related apoptosis-inducing ligand \(TRAIL\) target both tumor cells and tumor vasculature.](#)
*Adenovirus transduced CD34+ cells expressing membrane-bound tumor necrosis...*16th January, 2010
Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milano,- Blood. 2010 Jan 14. ([DOI Direct Link](#))
- [Bilateral whirlbone necrosis in a young multiple sclerosis patient.](#)
*A case of avascular necrosis of whirlbone in a young man affected by...*13th January, 2010
Division of Neurology, Istituto Nazionale Tumori Regina Elena, Via- Neurol Sci. 2010 Jan 12. ([DOI Direct Link](#))
- [Understanding pathogenetic aspects and clinical presentation of primary effusion lymphoma through its derived cell lines.](#)
*Primary effusion lymphoma (PEL) is a very rare subgroup of B-cell...*7th January, 2010
aDepartment of Pathology and Laboratory Medicine, Istituto Nazionale- AIDS. 2010 Jan 5. ([DOI Direct Link](#))
- [TP53 Mutations and Pathologic Complete Response to Neoadjuvant Cisplatin and Fluorouracil Chemotherapy in Resected Oral Cavity Squamous Cell Carcinoma.](#)
*PURPOSE: To find out if TP53 functional status predicts response to...*6th January, 2010
Unit of Experimental Molecular Pathology, Department of Pathology, and the- J Clin Oncol. 2010 Jan 4. ([DOI Direct Link](#))
- [Bortezomib As Induction Before Autologous Transplantation, Followed by Lenalidomide As Consolidation-Maintenance in Untreated Multiple Myeloma Patients.](#)
*PURPOSE: To evaluate the effect of bortezomib as induction therapy before...*6th January, 2010
Divisione di Ematologia dell'Universita di Torino and Unita di Ematologia,- J Clin Oncol. 2010 Jan 4. ([DOI Direct Link](#))
- [The enhancement of antiproliferative and proapoptotic activity of HDAC inhibitors by curcumin is mediated by Hsp90 inhibition.](#)
*Curcumin, a natural polyphenol, has been described to exhibit effects on...*30th December, 2009
Fondazione IRCCS Istituto Nazionale Tumori, Via Venezian 1, 20133, Milan,- Cell Mol Life Sci. 2009 Dec 29. ([DOI Direct Link](#))

Press Releases on Istituto Nazionale Tumori:

[RenalGuard\(R\) to be Demonstrated in Live Case at GISE 2009](#)

19th October, 2009

PLC Systems Inc.

FRANKLIN, Mass., Oct. 19 /PRNewswire-FirstCall/ -- PLC Systems Inc. (OTC Bulletin Board: PLCSF), a company focused on innovative cardiac and vascular medical device-based technologies, today announced

[Particulate Emission from Natural Gas Burning Home Appliances Is Assessed in Environmental Engineering Science Journal](#)

8th January, 2009

Mary Ann Liebert, Inc.

NEW ROCHELLE, N.Y., Jan. 8 /PRNewswire/ -- Natural gas, believed to be among the cleanest forms of fuel, does emit ultrafine airborne particulate matter when burned in home appliances such as stove

[Pediatric Patient Treated Using RapidArc\(TM\) Radiotherapy Technology in Switzerland](#)

22nd December, 2008

Varian Medical Systems

BELLINZONA, Switzerland, Dec. 22 /PRNewswire-FirstCall/ -- A Swiss cancer clinic is among the first in the world to use a new, faster radiotherapy technology from Varian Medical Systems (NYSE: VAR

[First Cancer Patients in Switzerland Treated Using RapidArc\(TM\) Technology from Varian Medical Systems](#)

15th September, 2008

Varian Medical Systems, Inc.

BELLINZONA, Switzerland, Sept. 15 /PRNewswire-FirstCall/ -- Doctors in Switzerland have carried out the country's first clinical treatments using RapidArc(TM) technology from Varian Medical

BioNews Results for Istituto Nazionale Tumori



- [Herceptin Again Proves Mettle Against Breast Cancer](#)
BusinessWeek: Jan 31 2010 3:15AM Matching: istituto nazionale tumori
- [Herceptin Again Proves Mettle Against Breast Cancer](#)
MedicineNet.com: Jan 30 2010 11:14AM Matching: istituto nazionale tumori
- [Adding Trastuzumab May Help in Advanced Breast Cancer](#)
Modern Medicine: Jan 29 2010 8:35PM Matching: istituto nazionale tumori
- [Herceptin Again Proves Mettle Against Breast Cancer](#)
EverydayHealth.com: Jan 29 2010 8:07PM Matching: istituto nazionale tumori
- [Herceptin Again Proves Mettle Against Breast Cancer](#)
HealthScout: Jan 29 2010 7:12PM Matching: istituto nazionale tumori
- [Herceptin Again Proves Mettle Against Breast Cancer](#)
Medbroadcast: Jan 29 2010 5:26PM Matching: istituto nazionale tumori
- [Herceptin Again Proves Mettle Against Breast Cancer](#)
MSN: Jan 29 2010 2:58PM Matching: istituto nazionale tumori
- [Herceptin Again Proves Mettle Against Breast Cancer](#)
National Womens Health Information Center: Jan 29 2010 1:17PM Matching: istituto nazionale tumori
- [Herceptin Again Proves Mettle Against Breast Cancer](#)
Yahoo! News: Jan 29 2010 5:47AM Matching: istituto nazionale tumori
- [Herceptin Again Proves Mettle Against Breast Cancer \(HealthDay\)](#)
Yahoo! News: Jan 29 2010 5:37AM Matching: istituto nazionale tumori
- [Herceptin Again Proves Mettle Against Breast Cancer \(HealthDay\)](#)
Yahoo! News: Jan 29 2010 5:26AM Matching: istituto nazionale tumori

- [Herceptin Again Proves Mettle Against Breast Cancer](#)
Health Day: Jan 29 2010 2:56AM Matching: istituto nazionale tumori
- [Traztuzumab improves outcome of HER2-positive locally advanced or inflammatory breast cancer](#)
MedWire News: Jan 29 2010 7:05PM Matching: istituto nazionale tumori
- [Trastuzumab Improves Event-Free Survival in HER2-Positive Locally Advanced or Inflammatory Breast Cancer](#)
Doctors Guide: Jan 29 2010 11:22AM Matching: istituto nazionale tumori
- [TP53 Mutations and Pathologic Complete Response to Neoadjuvant Cisplatin and Fluorouracil Chemotherapy in Rese](#)
Journal of Clinical Oncology: Jan 13 2010 12:46AM Matching: istituto nazionale tumori

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

